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Abstract 
Short communication on t(3;12)(q26;p13) 
ETV6/MECOM, with data on clinics, and the genes 
implicated. 
Identity 
Note 
Only a few cases were shown to involve a 
ETV6/MECOM fusion by FISH or RT-PCR. In 
other cases, only MECOM or ETV6 was shown to 
be rearranged by FISH. Over-expression of 
MECOM/EVI1 was found in other cases. Finally, 
no cytogenetic or molecular analysis was performed 
in a few cases. 
 
t(3;12)(q26;p13) G-banding - Courtesy Jean-Luc Lai and 
Alain Vanderhaegen.Clinics and pathology 
Disease 
Myeloid lineage: MDS in transformation, ANLL, 
BC-CML 
Phenotype/cell stem origin 
Multilineage involvement; MDS--> M0, M2, M4,  
M7. 
Epidemiology 
46 cases described so far; sex ratio: 29M/16F (1 
unknown); age: 2.5-87 yrs (med: 49 yrs), unknown 
age for 10 cases. 
Cytology 
Dysplasia of megakaryocytes, multilineage 
involvement. 
Prognosis 
See survival curve above. 
Cytogenetics 
Cytogenetics molecular 
Heterogeneity of the EVI1 breakpoints, as 
evidenced by the Cytocell Aquarius EVI1 
Breakapart probe.  
The EVI1 Breakapart probe contains three probes: a 
probe labeled in Aqua of 562 kb in size centromeric 
to the EVI1 gene, a probe labeled in Spectrum 
Green of 181 kb covering EVI1 and its flanking 
regions and a probe labeled in Spectrum Orange of 
124 kb telomeric of the EVI1 gene (telomeric of 
MYNN and covering LRRC34). 
Additional anomalies 
Sole anomaly in 22 cases.  
Additional anomalies: t(9;22)(q34;q11) in 5 cases, -
7/del(7q) in 11 cases, del(5q) in 2 cases, others in 6 
cases. 
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Survival curve (21 patients, Mean: 12 mths, Median: 10 mths). 
 
 
Genes involved and 
proteins 
MECOM 
Location 
3q26 
Note 
Alias EVI1 
DNA/RNA 
MECOM is a "complex entity" made of two genes, 
EVI1 and MDS1.  
EVI1 has 16 exons, of which 14 are coding, the 
start ATG codons being in exon 3.  
MDS1 has 4 exons, exon 4 being located in the 
vicinity of exon 1 of EVI1.  
Splicing of the second exon of MDS1 to the second 
exon of EVI1 leads to a MDS1-EVI1 mRNA. 
Protein 
EVI1 contains two domains of seven and three zinc 
finger motifs separated by a repression domain and 
an acidic domain at its C-terminus. 
ETV6 
Location 
12p13 
Note 
The ETV6 gene encodes a transcription factor 
frequently rearranged in myeloid and lymphoid 
leukemias. 
 
DNA/RNA 
The ETV6 gene spans a region of less than 250 kb 
at band 12p13.1 and consists of 8 exons. There are 
two start codons, one (exon 1a starting at codon 1) 
located at the beginning of the gene and another 
alternative (exon 1b starting at codon 43) upstream 
of exon 3. 
Protein 
The ETV6 protein (452 amino acids) contains two 
major domains, the HLH (helix-loop-helix) and 
ETS domains. The HLH domain, also referred to as 
the pointed or sterile alpha motif domain, is 
encoded by exons 3 and 4 and functions as a homo-
oligodimerization domain. The ETS domain, 
encoded by exons 6 through 8, is responsible for 
sequence specific DNA-binding and protein-protein 
interaction. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Two mechanisms for generating the fusion gene, 
depending upon the involvement of the MDS1 
gene. 
Transcript 
1) In-frame transcript consisting of the first two 
exons of ETV6 fused to MDS1 sequences, which in 
turn is fused to the second exon of the EVI1 gene. 
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Schematic diagram of the ETV6, EVI1, MDS1, MDS1-EVI1, ETV6-EVI1 and ETV6-MDS1-EVI1 proteins. 
 
2) Out-of-frame fusion by direct fusion between 
exon 2 of ETV6 and exon 2 of EVI1, but keeping 
the open reading frame of EVI1 intact. 
Fusion protein 
Description 
ETV6 contributes no known functional domain to 
the predicted chimeric protein but functional 
domains of EVI1 are retained. 
Oncogenesis 
The oncogenic potential of the translocation could 
be the result of the ETV6 promoter driving the 
transcription of EVI1. Because the ETV6 promoter 
is active in hematopoietic cells, this would result in 
inappropriate expression of the transcription factor 
EVI1. 
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